報價延遲最少15分鐘:2025/02/22 18:15 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
31.28 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
3.01/--
|
|
企業價值
2.12B
|
| 資產負債 |
|
每股賬面淨值
15.13
|
| 現金流量 |
|
現金流量率
0.13
|
| 損益表 |
|
收益
644.40M
|
|
每股收益
12.51
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/22 18:15 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has tworeportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |